Journal of Cardiovascular Disease Research ISSN:0975-3583,0976-2833 VOL12,ISSUE04,2021 2236 NEW ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR IN BULK AND PHARMACEUTICALDOSAGE FORMBYRP-UPLCMETHOD Sandhya Rani.Baratam 1* , Raghu Prasad Mailavaram 1 ,Rajendra Prasad Yejella 3 ,SurendraBabu lagu 4 ,Ramanamma Lalam 2 , Jagadeesh panda 2 1 Reserach scholar, Sri Vishnu college of Pharmacy, Affiliated to Andhra University, Bhimavaram 2 Professor, Raghu college of pharmacy, Affiliated to Andhra University, Visakhapatnam 3 Professor, Andhra University college of Pharmaceutical Sciences, Visakhapatnam, 4 Professor, AdikaviNannaya University college of Pharmaceutical Sciences, Tadepalligudem *Corresponding Author: SandhyaRani.Baratam, Research scholar, Sri Vishnu college of Pharmacy, Affiliated to Andhra University, HG9G+G3R, Garagaparru Road, Kovvada, Andhra Pradesh 534202, Email id: sandhtaranib@gmail.com, Orcid id: https://orcid.org/0000-0003-1811-333X ABSTRACT: A simple, specific and accurate reverse phase ultra-performance liquid chromatographic method was developed for the simultaneousdetermination Sofosbuvir and Velpatasvirin pharmaceutical dosage form. The column used was Kromosil C18(150mm x 4.6 mm, 5μm)inisocratic mode, with mobile phase containing phosphate buffer andacetonitrile(75:25v/v). The flow rate was 1.0ml/ min and effluents weremonitored at 260 nm. The retention times of Sofosbuvir and Velpatasvirwere found to be 2.404min and 2.986 min, respectively.The linearityfor Sofosbuvir and Velpatasvirwere in the range of 35-210μg/ml and 8-48 μg/ml respectively. The recoveries of Sofosbuvir andVelpatasvirwere found to be 99.64% and 99.25%, respectively. The proposed method was validated and successfully applied to the estimationofSofosbuvirandVelpatasvirincombinedtabletdosageforms. KEYWORDS:Sofosbuvir,Velpatasvir,Validation,BufferandICHGuidelines. INTRODUCTION Sofosbuvir 1 is an oral nucleoside analogue and powerful inhibitor of hepatitis C virus (HCV) RNA polymerase that is used to treat chronic hepatitis C in combination with other antiviral drugs. Nonetheless, successful antiviral therapy for hepatitis C with sofosbuvir and other direct acting agents in patients with cirrhosis is occasionally complicated by hepatic decompensation; additionally, treatment can cause reactivation of hepatitis B in susceptible patients coinfected with the hepatitis B virus for unknown reasons (HBV), IUPAC propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin- 1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate. Having the molecular formula C 22 H 29 FN 3 O 9 P with molecular weight 529.5.